DOI QR코드

DOI QR Code

Correlation Between Expression of Cell Adhesion Molecules CD44 v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer

  • Su, Chong-Yu (Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Li, Yun-Song (Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Han, Yi (Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Zhou, Shi-Jie (Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Liu, Zhi-Dong (Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University)
  • Published : 2014.03.01

Abstract

Objective: To explore the relationship between expressions of cell adhesion molecules CD44 v6 and E-cadherin (E-cad) and lymphatic metastasis in non-small cell lung cancer (NSCLC). Materials and Methods: Eightyseven tissue samples obtained from patients with primary NSCLC were collected in our hospital from Dec., 2007 to Dec., 2012, and the expressions of CD44 v6 and E-cad gene proteins in these samples were detected by immunohistochemical method. Results: In the tissue without lymphatic metastasis, the positive expression rate of CD44 v6 was significantly lower, whereas the normal expression rate of E-cad was notably higher than that with lymphatic metastasis (55.6% vs. 78.4%, 47.2% vs. 21.6%), and both differences had statistical significance (P<0.05). Besides, CD44 v6 and E-cad expressions had a significant correlation in the NSCLC tissue with lymphatic metastasis (P<0.05). Conclusions: The positive expression of CD44 v6 and abnormal expression of E-cad may play a very important role in promoting lymphatic metastasis of NSCLC, with synergistic effect. Hence, detection of CD44 v6 and E-cad expressions is conductive to judging the lymphatic metastasis in NSCLC.

References

  1. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  2. Liotta LA, Stetler-Stevenson WG (1991). Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 51, 5054s-9s.
  3. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  4. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  5. Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection (Yadanzi(R)) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791
  6. Nentwich MF, Bohn BA, Uzunoglu FG, et al (2013). Lymphatic invasion predicts survival in patients with early nodenegative non-small cell lung cancer. J Thorac Cardiovasc Surg, 146, 781-7. https://doi.org/10.1016/j.jtcvs.2013.04.037
  7. Shiwu WU, Lan Y, Wenqing S, et al (2012). Expression and clinical significance of CD82/KAI1 and E-cadherin in nonsmall cell lung cancer. Arch Iran Med, 15, 707-12.
  8. Sulzer MA, Leers MP, van Noord JA, et al (1998). Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med, 157, 1319-23. https://doi.org/10.1164/ajrccm.157.4.9703099
  9. Tran TA, Kallakury BV, Sheehan CE, et al (1997). Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol, 28, 809-14. https://doi.org/10.1016/S0046-8177(97)90154-4
  10. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  11. Gunthert U, Hofmann M, Rudy W, et al (1991). A new variant of glycoprotein $CD_{44}$ confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24. https://doi.org/10.1016/0092-8674(91)90403-L
  12. Hou ZB, Lu KJ, Wu XL, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment. Asian Pac J Cancer Prev, 15, 1767-9. https://doi.org/10.7314/APJCP.2014.15.4.1767
  13. Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. https://doi.org/10.7314/APJCP.2013.14.11.6663
  14. Kawano T, Yanoma S, Nakamura Y, et al (2005). Evaluation of soluble adhesion molecules $CD_{44}$ ($CD_{44}st$, $CD_{44}v5$, $CD_{44}v6$), ICAM-1, and VCAM-1 astumor markers in head and neck cancer. Am J Otolaryngol, 26, 308-13. https://doi.org/10.1016/j.amjoto.2005.02.005
  15. Kolesnik AP, Shevchenko AI, Tumanskii VA, et al (2013). Effect of the intercellular adhesion molecule E-cadherin on the prognosis of non-small cell lung cancer. Arkh Patol, 75, 30-3.
  16. Li C, Hong W (2013). Research status and funding trends of lung cancer biomarkers. J Thorac Dis, 5, 698-705.
  17. Li ZM, Ding ZP, Luo QQ, et al (2013). Prognostic significance of the extent of lymph node involvement in stage II-N1 nonsmall cell lung cancer. Chest, 144, 1253-60. https://doi.org/10.1378/chest.13-0073
  18. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  19. Cui L, Liu XX, Jiang Y, et al (2014). Phase II Study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
  20. Amirghofran Z, Jalali SA, Hosseini SV, et al (2008). Evaluation of $CD_{44}$ and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. J Gastrointest Cancer, 39, 73-8. https://doi.org/10.1007/s12029-009-9062-2
  21. Cazes A, Gibault L, Rivera C (2014). Lymphatic extension and lymphangiogenesis in non-small cell lung cancer. Rev Pneumol Clin, Epub ahead of print.
  22. Chai LX, Sun KL, Guo LP, et al (2007). Expression of ezrin and $CD_{44}$-v6 in human esophageal squamous cell carcinoma and its clinical significance. Chin J Oncol, 29, 685-8.
  23. Dursun P, Yuce K, Usubutun A, e al (2007). Loss of epithelium cadherin expression is associated with reduced overall survival and disease-free survival in early-stage squamous cell cervical carcinoma. Int J Gynecol Cancer, 17, 843-50. https://doi.org/10.1111/j.1525-1438.2007.00876.x
  24. Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 upregulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
  25. Frixen UH, Behrens J, Sachs M, et al (1991). E-cadherinmediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol, 113, 173-85. https://doi.org/10.1083/jcb.113.1.173
  26. Yin HT, Tian QZ, Guan L, et al (2013). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6. https://doi.org/10.7314/APJCP.2013.14.3.1703
  27. Warrington SJ, Strutt H, Strutt D et al (2013). The Frizzleddependent planar polarity pathway locally promotes E-cadherin turnover via recruitment of RhoGEF2. Development, 140, 1045-54. https://doi.org/10.1242/dev.088724
  28. Wendt MK, Taylor MA, Schiemann BJ, et al (2011). Downregulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell, 22, 2423-35. https://doi.org/10.1091/mbc.E11-04-0306
  29. Yan HA, Shen K, Huang XE, et al (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801
  30. Yin HT, Zhang DG, Wu XL, et al (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12. https://doi.org/10.7314/APJCP.2013.14.1.409
  31. Yip C, Cook GJ, Weeks A, et al (2014). Imaging assessment of lung tumor angiogenesis: insights and innovations. Semin Respir Crit Care Med, 35, 112-28. https://doi.org/10.1055/s-0033-1363457

Cited by

  1. Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6761
  2. Low Expression of the FoxO4 Gene may Contribute to the Phenomenon of EMT in Non-small Cell Lung Cancer vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4013
  3. Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells vol.36, pp.1, 2015, https://doi.org/10.3892/ijmm.2015.2222
  4. The clinicopathological significance and potential drug target of E-cadherin in NSCLC vol.36, pp.8, 2015, https://doi.org/10.1007/s13277-015-3298-1
  5. Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics vol.467, pp.1, 2015, https://doi.org/10.1007/s00428-015-1767-y
  6. Prognostic value of cancer stem cell markers and E-cadherin expression in non-small-cell lung cancer vol.37, pp.2, 2017, https://doi.org/10.1097/01.XEJ.0000526548.59367
  7. C3G dynamically associates with nuclear speckles and regulates mRNA splicing vol.29, pp.9, 2018, https://doi.org/10.1091/mbc.E17-07-0442
  8. Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma pp.1573-4919, 2019, https://doi.org/10.1007/s11010-019-03500-3